Comparison of Pegfilgrastim Prescribing Practice to National Guidelines at a University Hospital Outpatient Oncology Clinic-Reference-Cited by-同舟云学术

Comparison of Pegfilgrastim Prescribing Practice to National Guidelines at a University Hospital Outpatient Oncology Clinic

Published:2013-07 Issue:4 Volume:9 Page:203-206
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Waters Geralyn E.¹,Corrigan Patricia¹,Gatesman Mandy¹,Smith Thomas J.¹

Affiliation:

1. University of Virginia Health System, Charlottesville; Virginia Commonwealth University Health System, Richmond, VA; Johns Hopkins Medical Institutions; Sidney Kimmel Comprehensive Cancer Center; and Johns Hopkins Medicine, Baltimore, MD

Abstract

At one institution, approximately one half of primary prophylaxis pegfilgrastim was not indicated per published guidelines, highlighting a need to change prescribing practices, to reduce costs without harming patients.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology(nursing),Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JOP.2012.000662

Reference24 articles.

1. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline

2. Myeloid Growth Factors

3. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

4. Granulocyte Colony-Stimulating Factor Use in Cancer Patients

5. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Afebrile chemotherapy-induced neutropenia: an international survey spots oncologists’ routine clinical practice versus the standard of care and the impact of COVID-19;Supportive Care in Cancer;2022-10-29

2. Granulocyte Colony-Stimulating Factor Utilization and Prescribing Patterns in Cancer Patients: A Single Institution Experience of a Saudi Cancer Center;Cureus;2022-07-19

3. Underutilisation of prophylactic G-CSF in breast cancer patients receiving adjuvant docetaxel/cyclophosphamide chemotherapy;Journal of Chemotherapy;2021-12-06

4. Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019;JAMA Network Open;2021-11-23

5. Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer;The Breast;2021-06